Author: Louis Navellier and the InvestorPlace Research Staff

The company’s Covid-19 vaccine candidate is now in stage 3 clinical trials, and the company already has several big purchase orders in place.

These stocks aren’t going to wow you with growth, but their quarterly dividend is a big draw.

Any of its dips should be bought with both hands.

Each of these names are primed for low-risk, long-term growth.

Despite near-triple digit returns this year, it still has room to run.